Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Adaptive Biotechnologies (ADPT) Misses Q4 EPS by 4c
February 24, 2021 4:24 PM ESTAdaptive Biotechnologies (NASDAQ: ADPT) reported Q4 EPS of ($0.33), $0.04 worse than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.2 million versus the consensus estimate of $26.9 million.
"Adaptive's launch of T-Detect COVID marks a pivotal moment in the diagnostic testing... More
